GUCY2C molecular staging personalizes colorectal cancer patient management.

Abstract

While the most significant prognostic and predictive marker in the management of colorectal cancer patients is cancer cells in regional lymph nodes, approximately 30% of patients whose lymph nodes are ostensibly free of tumor cells by histopathology ultimately develop recurrent disease reflecting occult metastases. Molecular techniques utilizing highly specific markers and ultra-sensitive detection technologies have emerged as powerful staging platforms to establish prognosis and predict responsiveness to chemotherapy in colorectal cancer patients. This review describes the evolution of the tumor suppressor GUCY2C as a prognostic and predictive molecular biomarker that quantifies occult tumor burden in regional lymph nodes for staging patients with colorectal cancer.

• Authors: Jian P Gong, Stephanie Schulz, Terry Hyslop, Scott A Waldman
• Journal: Biomarkers in medicine (Biomark Med) Vol. 6 Issue 3 Pg. 339-48 (Jun 2012) ISSN: 1752-0371 [Electronic] England
• PMID: 22731908 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Biomarkers, Tumor
• Receptors, Peptide
• GUCY2C protein, human
• Receptors, Enterotoxin
• Receptors, Guanylate Cyclase-Coupled

Topics

• Biomarkers, Tumor (analysis, genetics, metabolism)
• Colorectal Neoplasms (diagnosis, genetics, metabolism, pathology)
• Humans
• Neoplasm Staging
• Precision Medicine
• Receptors, Enterotoxin
• Receptors, Guanylate Cyclase-Coupled (genetics, metabolism)
• Receptors, Peptide (genetics, metabolism)